Literature DB >> 8227406

Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro.

D M Keeling1, A J Wilson, I J Mackie, D A Isenberg, S J Machin.   

Abstract

AIMS: To investigate the effect of beta 2-glycoprotein I (beta 2 GPI) on the thrombin/thrombomodulin dependent activation of protein C; and to determine whether beta 2 GPI dependent anticardiolipin antibodies have any effect.
METHODS: Protein C was activated by thrombin in the presence of thrombomodulin and phospholipid vesicles in an in vitro system. The effect of adding purified beta 2 GPI to this system was observed. Affinity purified anticardiolipin antibodies and total IgG from patients with anticardiolipin antibodies and the lupus anticoagulant were studied for their effects on protein C activation in the presence and absence of beta 2 GPI.
RESULTS: beta 2-Glycoprotein I had no effect on the activity of preformed activated protein C. When the phospholipid vesicles were incubated with beta 2 GPI before the addition of protein C, the activation of protein C was inhibited in a dose dependent manner. With phosphatidylserine:phosphatidylcholine vesicles at a concentration of 1 microM:2 microM, beta 2 GPI began to inhibit the reaction at a concentration of 15 nM, and at 4 microM (the normal plasma concentration) the activation of protein C was reduced to 40%. Anticardiolipin antibodies had no demonstrable effect.
CONCLUSIONS: beta 2-Glycoprotein I inhibits protein C activation in an in vitro system. Its physiological role is unknown but it has potential procoagulant as well as anticoagulant properties. An effect of antiphospholipid antibodies on protein C activation, which might explain their association with thrombosis, could not be shown.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227406      PMCID: PMC501616          DOI: 10.1136/jcp.46.10.908

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  35 in total

1.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

2.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Koike
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

3.  Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies.

Authors:  R G Malia; S Kitchen; M Greaves; F E Preston
Journal:  Br J Haematol       Date:  1990-09       Impact factor: 6.998

4.  Inhibition of the activation of Hageman factor (factor XII) by beta 2-glycoprotein I.

Authors:  M L Henry; B Everson; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1988-05

5.  Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant.

Authors:  E Marciniak; E H Romond
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

6.  In vitro activation of the contact activation system (Hageman factor system) in plasma by acidic phospholipids and the inhibitory effect of beta 2-glycoprotein I on this activation.

Authors:  I Schousboe
Journal:  Int J Biochem       Date:  1988

7.  Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation.

Authors:  R Cariou; G Tobelem; S Bellucci; J Soria; C Soria; J Maclouf; J Caen
Journal:  Thromb Haemost       Date:  1988-08-30       Impact factor: 5.249

8.  A second plasma inhibitor of activated protein C: alpha 1-antitrypsin.

Authors:  F J van der Meer; N H van Tilburg; A van Wijngaarden; I K van der Linden; E Briët; R M Bertina
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

9.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

10.  Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.

Authors:  E M Bevers; M Galli; T Barbui; P Comfurius; R F Zwaal
Journal:  Thromb Haemost       Date:  1991-12-02       Impact factor: 5.249

View more
  10 in total

1.  Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors.

Authors:  Kristi L Allen; Anne Hamik; Mukesh K Jain; Keith R McCrae
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

2.  Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.

Authors:  Masahiro Ieko; Mika Yoshida; Sumiyoshi Naito; Toru Nakabayashi; Kaoru Kanazawa; Kazuhiro Mizukami; Masaya Mukai; Tatsuya Atsumi; Takao Koike
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

3.  Analysis of variable region genes encoding anti-Sm and anti-cardiolipin antibodies from a systemic lupus erythematosus patient.

Authors:  C Demaison; C T Ravirajan; D A Isenberg; M Zouali
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

4.  Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

Authors:  T Atsumi; M A Khamashta; O Amengual; S Donohoe; I Mackie; K Ichikawa; T Koike; G R Hughes
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

Review 5.  Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome.

Authors:  Juan J Fierro; Manuela Velásquez; Angela P Cadavid; Karina de Leeuw
Journal:  Am J Reprod Immunol       Date:  2021-12-04       Impact factor: 3.777

Review 6.  The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS.

Authors:  Thomas McDonnell; Chris Wincup; Ina Buchholz; Charis Pericleous; Ian Giles; Vera Ripoll; Hannah Cohen; Mihaela Delcea; Anisur Rahman
Journal:  Blood Rev       Date:  2019-08-16       Impact factor: 10.626

Review 7.  Coagulation and Fibrinolysis in Obstructive Sleep Apnoea.

Authors:  Andras Bikov; Martina Meszaros; Esther Irene Schwarz
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

Review 8.  Persistence of Lipoproteins and Cholesterol Alterations after Sepsis: Implication for Atherosclerosis Progression.

Authors:  Krzysztof Laudanski
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 6.208

9.  The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients.

Authors:  Mark Jaradeh; Nausheen Baig; Emily Bontekoe; Mirjana Mitrovic; Darko Antic; Debra Hoppensteadt; Bulent Kantarcioglu; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

10.  Significance of K(L/V)WX(I/L/V)P Epitope of the B2Gpi in Its (Patho)Physiologic Function.

Authors:  Urška Žager; Mojca Lunder; Vesna Hodnik; Gregor Anderluh; Saša Čučnik; Tanja Kveder; Borut Božič
Journal:  EJIFCC       Date:  2011-12-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.